Characteristics | Total population (n=62) |
Demographics | |
Age (years) (mean (SD)) | 67.3 (12.8) |
Male (n (%)) | 53 (85.5) |
Body mass index (kg/m2) (median (IQR)) | 27.1 (26.1 to 30.9) |
Daily alcohol >30 g (n (%)) | 9 (15.8) |
Excessive sugar-sweetened beverage intake (n (%)) | 1 (1.6) |
Purine-rich diet (n (%)) | 10 (17.9) |
Gout characteristics | |
Symptom duration (years) (median (IQR)) | 10 (3–16) |
Subcutaneous tophi (n (%)) | 26 (41.9) |
Number of flares in past 6 months (median (IQR)) | 2 (1–3) |
Urate-lowering therapy naive (n (%)) | 41 (66.1) |
Comorbidities | |
History of urolithiasis (n (%)) | 12 (19.7) |
Hypertension (n (%)) | 45 (72.6) |
Chronic heart failure (n (%)) | 18 (29.0) |
History of myocardial infarction (n (%)) | 11 (17.7) |
Coronary heart disease (n (%)) | 13 (21.0) |
Cardiovascular disease | 26 (41.9) |
History of stroke (n (%)) | 2 (3.2) |
Dyslipidaemia (n (%)) | 29 (46.8) |
Diabetes mellitus (n (%)) | 18 (29.0) |
Obstructive sleep apnoea (n (%)) | 7 (11.3) |
Treatments | |
Diuretics (n (%)) | 19 (30.6) |
Lipid-lowering drugs (n (%)) | 30 (48.4) |
Antihypertensive drugs (n (%)) | 44 (71.0) |
Antiplatelet/anticoagulants | 30 (48.4) |
Laboratory findings | |
Serum urate level (mg/dL) (median (IQR)) | 8.4 (6.6–9.9) |
Estimated glomerular filtration rate <60 mL/min/1.73 m2 (n (%)) | 14 (24.6) |
Dual-energy CT volumes of MSU crystal deposits | |
Feet (cm3) (median (IQR)) | 0.5 (0.2–1.9) |
Knees (cm3) (median (IQR)) | 0.4 (0.1–1.2) |
Total (cm3) (median (IQR)) | 1 (0.4–2.7) |
MSU, monosodium urate.